The use of the D1/D2 dopamine receptor agonist apomorphine for the treatment of erectile dysfunction provides strong support in favor of a participation of the dopaminergic system in the control of sexual function. However, the exact involvement of dopamine in the control of sexual motivation and genital arousal in males is unknown. Experimental data in male rats suggested an implication of dopamine in sexual motivation as well as in copulatory performance. Specific tests allowing assessment of sexual motivation showed that the release of dopamine at the level of the nucleus accumbens (innervated by the mesolimbic dopaminergic pathway) and the medial preoptic area of the hypothalamus (innervated by the dopaminergic incertohypothalamic pathway) positively regulated the anticipatory/motivational phase of copulatory behavior. A permissive role of dopamine released at the level of the median preoptic area of the hypothalamus in the display of copulatory behavior has also been demonstrated. It is noteworthy that these participations of the dopaminergic system are not specific for sexual behavior but rather reflect the involvement of dopamine in the regulation of cognitive, integrative and reward processes. Because of its role in the control of locomotor activity, the integrity of the nigrostriatal dopaminergic pathway is also essential for the display of copulatory behavior. Somehow more specific to sexual function, it is likely that dopamine can trigger penile erection by acting on oxytocinergic neurons located in the paraventricular nucleus of the hypothalamus, and perhaps on the proerectile sacral parasympathetic nucleus within the spinal cord. In conclusion, central dopamine is a key neurotransmitter in the control of sexual function.

Keywords:
Erectile dysfunction, Apomorphine, D1/D2 dopamine receptor agonist, Sexual function
1.
Steers WD: Neural pathways and central sites involved in penile erection: Neuroanatomy and clinical implications. Neurosci Biobehav Rev 2000;24:507–516.
2.
McKenna K: The brain is the master organ in sexual function: Central nervous system control of male and female sexual function. Int J Impot Res 1999;11(suppl 1):S48–S55.
3.
Giuliano F, Rampin O: Central neural regulation of penile erection. Neurosci Biobehav Rev 2000;24:517–533.
4.
Heaton JP: Central neuropharmacological agents and mechanisms in erectile dysfunction: The role of dopamine. Neurosci Biobehav Res 2000;24:561–569.
5.
Courty E, Durif F, Zenut M, Courty P, Lavarenne J: Psychiatric and sexual disorders induced by apomorphine in Parkinson’s disease. Clin Neuropharmacol 1997;20:140–147.
6.
Uitti RJ, Tanner CM, Rajput AH, Goetz CG, Klawans HL, Thiessen B: Hypersexuality with antiparkinsonian therapy. Clin Neuropharmacol 1989;12:375–383.
7.
Bowers MB, Van Woert M, Davis L: Sexual behavior during L–dopa treatment for Parkinsonism. Am J Psychiatry 1971;127:1691–1693.
8.
O’Brien CP, DiGiacomo JN, Fahn S, Schwarz GA: Mental effects of high–dosage levodopa. Arch Gen Psychiatry 1971;24:61–64.
9.
Goodwin FK: Psychiatric side effects of levodopa in man. JAMA 1971;218:1915–1920.
10.
Bommer J, Ritz E, del Prozo E, Bommer G: Improved sexual function in male haemodialysis patients on bromocriptine. Lancet 1979;ii: 496–497.
11.
March CM: Bromocriptine in the treatment of hypogonadism and male impotence. Drugs 1979;17:349–358.
12.
Ambrosi B, Bara R, Travaglini P, Weber G, Beck Peccoz P, Rondena M, Elli R, Faglia G: Study of the effects of bromocriptine on sexual impotence. Clin Endocrinol (Oxf) 1977;17: 349–358.
13.
Gooren L: Preliminary evidence that not prolactin itself, but the underlying dopaminergic dysregulation causes male sexual dysfunction in the cases of hyperprolactinemia. Int Acad Sex Res, August 16, 1986, The Netherlands.
14.
Petty RG: Prolactin and antipsychotic medications: Mechanism of action. Schizophr Res 1999;35(suppl):S67–S73.
15.
Lal S, Ackman D, Thavundayil JX, Kiely ME, Etienne P: Effect of apomorphine, a dopamine receptor agonist, on penile tumescence in normal subjects. Prog Neuropsychopharmacol Biol Psychiatry 1984;8:695–699.
16.
Heaton JP: Apomorphine: an update of clinical trial results. Int J Impot Res 2000;12(suppl 4): S67–S73.
17.
Melis MR, Argiolas A: Dopamine and sexual behavior. Neurosc Biobehav Rev 1995;19:19– 38.
18.
Weiner N, Molinoff PB: Catecholamines; in Siegel G, Agranoff B, Albers RW, Molinoff P (eds): Basic Neurochemistry. New York, Raven Press, 1989, pp 233–251.
19.
Sourkes TL: Disorders of the basal ganglia; in Siegel G, Agranoff B, Albers RW, Molinoff P (eds): Basic Neurochemistry. New York, Raven Press, 1989, pp 811–825.
20.
Seeman P: Dopamine receptors; in Bloom FE, Kupfer DJ (eds): Psychopharmacology: The Fourth Generation of Progress. New York, Raven Press, 1995, pp 295–302.
21.
Le Moal M, Simon H: Mesocorticolimbic dopaminergic network: Functional and regulatory roles. Physiol Rev 1991;71:155–234.
22.
Lindvall O, Bjorklund A, Skagerberg G: Selective histochemical demonstration of dopamine terminal systems in rat di– and telencephalon: New evidence for dopaminergic innervation of hypothalamic neurosecretory nuclei. Brain Res 1984;306:19–30.
23.
Buijs RM, Geffard M, Pool CW, Hoorneman EM: The dopaminergic innervation of the supraoptic and paraventricular nucleus. A light and electron microscopical study. Brain Res 1984;323:65–72.
24.
Melis MR, Argiolas A, Gessa GL: Apomorphine–induced penile erection and yawning: site of action in brain. Brain Res 1987;415:98– 104.
25.
Chen KK, Chan JY, Chang LS: Dopaminergic neurotransmission at the paraventricular nucleus of hypothalamus in central regulation of penile erection in the rat. J Urol 1999;162: 237–242.
26.
Andersson KE, Gemalmaz H, Waldeck K, Chapman TN, Tuttle JB, Steers WD: The effect of sildenafil on apomorphine–evoked increases in intracavernous pressure in the awake rat. J Urol 1999;161:1707–1712.
27.
Benassi–Benelli A, Ferrari F, Quarantotti BP: Penile erection induced by apomorphine and N–n–propyl–norapomorphine in rats. Arch Int Pharmacodyn Ther 1979;242:241–247.
28.
Mermet C, Gonon F: In vivo voltammetric monitoring of noradrenaline release and catecholamine metabolism in the hypothalamic paraventricular nucleus. Neuroscience 1986; 19:829–838.
29.
Commissiong JW, Galli CL, Neff NH: Differentiation of dopaminergic and noradrenergic neurons in rat spinal cord. J Neurochem 1978; 30:1095–1099.
30.
Skagerberg G, Lindvall O: Organization of diencephalic dopamine neurones projecting to the spinal cord in the rat. Brain Res 1985;342: 340–351.
31.
Ridet JL, Sandillon F, Rajaofetra N, Geffard M, Privat A: Spinal dopaminergic system of the rat: Light and electron microscopic study using an antiserum against dopamine, with particular emphasis on synaptic incidence. Brain Res 1992;598:233–241.
32.
Holstege JC, van Dijken H, Buijs RM, Goedknegt H, Gosens T, Bongers CM: Distribution of dopamine immunoreactivity in the rat, cat and monkey spinal cord. J Comp Neurol 1996; 376:631–652.
33.
Scatton B, Dubois A, Cudennec A: Autoradiographic localization of dopamine receptors in the spinal cord of the rat using [3H]–N–propylnorapomorphine. J Neural Transm 1984;59: 251–256.
34.
Van Dijken H, Dijk J, Voom P, Holstege JC: Localization of dopamine D2 receptor in rat spinal cord identified with immunocytochemistry and in situ hybridization. Eur J Neurosci 1996;8:621–628.
35.
Giuliano F, Allard J, Rampin O, Droupy S, Benoit G, Alexandre L, Bernabé J: Spinal proerectile effect of apomorphine in the anesthetized rat. Int J Impot Res 2001;13:110–115.
36.
Giuliano F, Allard J, Rampin O, Droupy S, Alexandre L, Bernabé J: Proerectile effect of systemic apomorphine. J Urol, in press.
37.
Ishizuka O, Gu BJ, Nishizawa O, Mizusawa H, Andersson KE: Effect of apomorphine on intracavernous pressure and blood pressure in conscious, spinalized rats. J Urol 2001;165 (suppl 5):918.
38.
Stefanick ML, Smith ER, Clark JT, Davidson JM: Effects of a potent dopamine receptor agonist, RDS–127, on penile reflexes and seminal emission in intact and spinally transected rats. Physiol Behav 1982;29:973–978.
39.
Pehek EA, Thompson JT, Hull EM: The effects of intrathecal administration of the dopamine agonist apomorphine on penile reflexes and copulation in the male rat. Psychopharmacology (Berl) 1989;99:304–308.
40.
Hansen S: Spinal control of sexual behavior: Effects of intrathecal administration of lisuride. Neurosci Lett 1982;33:329–332.
41.
Sachs BD, Meisel RL: The physiology of male sexual behavior; in Knobil E, Neil J (eds): The Physiology of Reproduction. New York, Raven Press, 1988, pp 1993–1485.
42.
Hull EM, Bitran D, Pehek EA, Warner RK, Ban LC, Holmes GM: Dopaminergic control of male sex behavior in rats: effects of an intracerebrally–infused agonist. Brain Res 1986; 370:73–81.
43.
Hull EM, Bazzett TJ, Warner RK, Eaton RC, Thompson JT: Dopamine receptors in the ventral tegmental area modulate male sexual behavior in rats. Brain Res 1990;512:1–6.
44.
Pfaus JG, Phillips AG: Role of dopamine in anticipatory and consummatory aspects of sexual behavior in the male rat. Behav Neurosci 1991;105:727–743.
45.
Pfaus JG, Everitt BJ: The psychopharmacology of sexual behavior; in Bloom FE, Kupfer DJ (eds): Psychopharmacology: The Fourth Generation of Progress. New York, Raven Press, 1995, pp 743–757.
46.
Everitt BJ: Sexual motivation: A neural and behavioural analysis of the mechanisms underlying appetitive and copulatory responses of male rats. Neurosci Biobehav Rev 1990;14: 217–232.
47.
Damsma G, Pfaus JG, Wenkstern D, Phillips AG, Fibiger HC: Sexual behavior increases dopamine transmission in the nucleus accumbens and striatum of male rats: Comparison with novelty and locomotion. Behav Neurosci 1992;106:181–191.
48.
Wenkstern D, Pfaus JG, Fibiger HC: Dopamine transmission increases in the nucleus accumbens of male rats during their first exposure to sexually receptive female rats. Brain Res 1993;618:41–46.
49.
Stefanick ML, Davidson JM: Genital responses in noncopulators and rats with lesions in the medial preoptic area or midthoracic spinal cord. Physiol Behav 1987;41:439–444.
50.
Pehek EA, Warner RK, Bazzett TJ, Bitran D, Band LC, Eaton RC, Hull EM: Microinjection of cis–flupenthixol, a dopamine antagonist, into the medial preoptic area impairs sexual behavior of male rats. Brain Res 1988;443:70– 76.
51.
Hull EM, Warner RK, Bazzett TJ, Eaton RC, Thompson JT, Scaletta LL: D2/D1 ratio in the medial preoptic area affects copulation of male rats. J Pharmacol Exp Ther 1989;251:422– 427.
52.
Simerly RB, Swanson LW: Projections of the medial preoptic nucleus: A Phaseolus vulgaris leucoagglutinin anterograde tract–tracing study in the rat. J Comp Neurol 1988;270:209–242.
53.
Hull EM, Eaton RC, Moses J, Lorrain D: Copulation increases dopamine activity in the medial preoptic area of male rats. Life Sci 1993; 52:935–940.
54.
Pomerantz SM: Dopaminergic influences on male sexual behavior of rhesus monkeys: Effects of dopamine agonists. Pharmacol Biochem Behav 1992;41:511–517.
55.
Pomerantz SM: Quinelorane (LY163502), a D2 dopamine receptor agonist, acts centrally to facilitate penile erections of male rhesus monkeys. Pharmacol Biochem Behav 1991;39: 123–128.
56.
Montorsi F, Salonia A, Scifo P, Anchisi D, Rigiroli P, Zanoni M, Fazio Ferruccio F, Rigatti P: Human cerebral activation by apomorphine after neutral and erotic visual stimulation: Results of a double blind, placebo controlled study with functional MRI of the brain. J Urol 2001;165(suppl 5):913.
57.
Stoleru S, Gregoire MC, Gerard D, Decety J, Lafarge E, Cinotti L, Lavenne F, Le Bars D, Vernet–Maury E, Rada H, Collet C, Mazoyer B, Forest MG, Magnin F, Spira A, Comar D: Neuroanatomical correlates of visually evoked sexual arousal in human males. Arch Sex Behav 1999;28:1–21.
58.
Krane R, Brock G, Eardley F, Fourcroy F, Guiliano F, Hutter C, Teloken M, Vickers M: Oral non endocrine treatment; in Jardin A, Wagner G, Khoury S, Giuliano F, Padma–Nathan H, Rosen R (eds): Erectile Dysfunction. Plymouth, Health Publication, 1999, pp 241–303.
59.
Civelli O: Molecular biology of the dopamine receptor subtypes; in Bloom FE, Kupfer DJ (eds): Psychopharmacology: The Fourth Generation of Progress. New York, Raven Press, 1995, pp 155–161.
2002
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.